ASRT Assertio Holdings, Inc. logo

ASRT Assertio Holdings, Inc.

Healthcare
$23.44+0.30%ClosedMarket Cap: $151.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

1.99

P/S

1.48

EV/EBITDA

41.33

DCF Value

$96.32

FCF Yield

-4.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

44.3%

Operating Margin

-22.3%

Net Margin

-34.9%

ROE

-38.7%

ROA

-16.9%

ROIC

-19.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$9.9M$-18.9M$
Q4 null$13.5M$-11.9M$
FY null$118.7M$-30.4M$
Q3 null$49.5M$11.4M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$22.65

Target (Median)

$22.65

Target Range

$21.80 - $23.50

0 Strong Buy1 Buy3 Hold0 Sell0 Strong Sell
Lake StreetHold
2026-05-13
HC Wainwright & Co.Neutral
2026-05-05
Lake StreetHold
2026-04-09
HC Wainwright & Co.Buy
2026-01-05
HC Wainwright & Co.Buy
2025-08-12

Trading Activity

Insider Trades

View All
Mason Heather Ldirector
SellFri May 15
Stark David Matthewdirector
SellWed May 06
MCKEE WILLIAMdirector
SellWed May 06
Mason Heather Ldirector
SellWed May 06
Kirk Sigurddirector
SellWed May 06

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

0.45

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Peers